Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 7CNS 4Sarcoma 2Other hematologic neoplasm 2Dermatologic 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Paclitaxel 31Cyclophosphamide 25Trastuzumab 23Doxorubicin 17Docetaxel 15Carboplatin 15pembrolizumab 13Radiotherapy 11Letrozole 11Capecitabine 11exemestane 10Fulvestrant 10Magnetic Resonance Spectroscopy 8Lapatinib 8Biopsy 8eribulin 7abemaciclib 7Taxes 7Bevacizumab 7Anastrozole 7pertuzumab 6palbociclib 6Neoadjuvant Therapy 6Goserelin 6Drug Therapy 6Aromatase Inhibitors 6130-nm albumin-bound paclitaxel 6Therapeutics 5Saline Solution 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carmustine × Breast × Clear all
NCT00006123 2018-05-16

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡